University of Oxford Confidence in Concept – Round 7
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding
People |
ORCID iD |
| Matthew Wood (Principal Investigator) |
Publications
Issa F
(2022)
Editorial: Regulatory T Cells
in Frontiers in Cell and Developmental Biology
Pilat N
(2022)
Joining Forces in Basic Science: ITS Meeting 2.0.
in Transplant international : official journal of the European Society for Organ Transplantation
VanDyke D
(2022)
Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.
in Cell reports
Staurenghi F
(2022)
Minicircle Delivery to the Neural Retina as a Gene Therapy Approach.
in International journal of molecular sciences
Leng H
(2022)
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.
in Nature communications
Kaukonen M
(2022)
CRISPR DNA Base Editing Strategies for Treating Retinitis Pigmentosa Caused by Mutations in Rhodopsin.
in Genes
Wing PAC
(2022)
Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model.
in PLoS pathogens
Stevanovic M
(2022)
CRISPR Systems Suitable for Single AAV Vector Delivery.
in Current gene therapy
Wright S
(2022)
Chimeric Antigen Receptors and Regulatory T Cells: The Potential for HLA-Specific Immunosuppression in Transplantation
in Engineering
| Description | BRAINSTATE - To develop the DyNeuMo device for use in minimally conscious state (Alex Green) |
| Amount | £697,119 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 07/2022 |
| End | 07/2025 |
| Description | Developing CRISPR delivery strategies for the treatment of inherited retinal diseases |
| Amount | £60,000 (GBP) |
| Organisation | The Royal College of Surgeons of Edinburgh |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 09/2021 |
| Description | ReSHAPE |
| Amount | £151,875 (GBP) |
| Funding ID | 825392 |
| Organisation | European Commission H2020 |
| Sector | Public |
| Country | Belgium |
| Start | 01/2019 |
| End | 12/2023 |
| Description | UCB Pharma |
| Organisation | UCB SA |
| Department | UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The key preliminary data generated by this project has been used to successfully negotiate a new partnership with our industrial collaborator UCB Pharma |
| Collaborator Contribution | providing antibody production to take place with no associated costs required from Oxford. |
| Impact | n/k |
| Start Year | 2022 |
| Title | MODULATING WAKEFULNESSS AND AROUSAL |
| Description | Arousal of a patient is enhanced and wakefulness modulated by neurostimulation. Bioelectrical activity of the nervous system of the patient is monitored and characteristics of the monitored bioelectrical activity associated with a state of reduced arousal and/or wakefulness are detected. In response to such characteristics, stimulation signals selected to arouse the patient are generated and supplied to stimulation transducers to stimulate a neural network of a patient associated with arousal. |
| IP Reference | WO2022200814 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2022 |
| Licensed | No |
| Impact | NK |
| Description | Experts in Residence meeting with Astra Zeneca |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | The purpose of the session was to discuss the longer term translational implications of the project via the experts in residence scheme. A wealth of information was transmitted to our research team on the validation routes for the project and how to consolidate the engagement and the collaboration prospects on this award. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Industry engagement activities with Kymab / Sanofi |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | The project team has been discussing a collaboration project with Kymab / Sanofi. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Industry engagement activities with UCB Pharma - (Alison Simmons) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | Discussing potential licensing agreement, pending data from larger sets of efficacy studies and safety/toxicology profiling of our monoclonal antibodies. |
| Year(s) Of Engagement Activity | 2021 |